Literature DB >> 33113336

Advances in Human Lung Transplantation.

Aparna C Swaminathan1,2, Jamie L Todd1,2, Scott M Palmer1,2.   

Abstract

Lung transplantation improves survival and quality of life in patients with advanced pulmonary disease. Over the past several decades, the volume of lung transplants has grown substantially, with increasing transplantation of older and acutely ill individuals facilitated by improved utilization and preservation of available donor organs. Other advances include improvements in the diagnosis and mechanistic understanding of frequent post-transplant complications, such as primary graft dysfunction, acute rejection, and chronic lung allograft dysfunction (CLAD). CLAD occurs as a result of the host immune response to the allograft and is the principal factor limiting long-term survival after lung transplantation. Two distinct clinical phenotypes of CLAD have emerged, bronchiolitis obliterans syndrome and restrictive allograft syndrome, and this distinction has enabled further understanding of underlying immune mechanisms. Building on these advances, ongoing studies are exploring novel approaches to diagnose, prevent, and treat CLAD. Such studies are necessary to improve long-term outcomes for lung transplant recipients.

Entities:  

Keywords:  bronchiolitis obliterans; graft rejection; lung transplantation; organ preservation; primary graft dysfunction

Year:  2020        PMID: 33113336     DOI: 10.1146/annurev-med-080119-103200

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  3 in total

Review 1.  Gene Therapy: Will the Promise of Optimizing Lung Allografts Become Reality?

Authors:  Qimeng Gao; Isabel F DeLaura; Imran J Anwar; Samuel J Kesseli; Riley Kahan; Nader Abraham; Aravind Asokan; Andrew S Barbas; Matthew G Hartwig
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

2.  Allo-reactive tissue-resident T cells causing damage: An inside job.

Authors:  René A W van Lier; Pleun Hombrink
Journal:  J Exp Med       Date:  2022-03-14       Impact factor: 17.579

3.  Interleukin-18: A Novel Participant in the Occurrence, Development, and Drug Therapy of Obliterative Bronchiolitis Postlung Transplantation.

Authors:  Ping Shu; Wei Zhang; Yanfei Zhang; Yanfeng Zhao; Yuping Li; Xiaoqing Zhang
Journal:  Dis Markers       Date:  2021-07-27       Impact factor: 3.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.